SLC5A2 and myocardial infarction: Using the SGLT2 inhibitor, canagliflozin, in a reverse-translational study, we found that long-term pre-administration over 4 weeks led to a significant attenuation of myocardial infarct size in both diabetic Zucker Diabetic Fatty (ZDF) and nondiabetic Zucker Lean (ZL) rats.